Special Issue

Current and Future Therapeutic Approaches to the Fentanyl Crisis

Message from the Guest Editor

The opioid epidemic driven by fentanyl is a clear and present danger to our society. Fentanyl in itself and when purposefully or accidentally taken with other drugs such as cocaine, heroin and methamphetamine (there is growing instances of these drugs being laced with fentanyl) leads to deaths via opioid-induced respiratory depression (OIRD) and also to addiction and physical dependence. Current medical assistance treatment (MAT) programs developed to treat heroin use disorder. such as those incorporating buprenorphine, are not proving successful for fentanyl use disorder. Moreover. opioid receptor antagonists are proving less than efficacious in attempting to reverse OIRD caused by fentanyl and especially fentanyl in combination with other drugs that disturb respiratory function such as those mentioned above. This Special Issue "Current and future therapeutic approaches to the fentanyl crisis " seeks inputs (reviews, commentaries, original research articles) from clinicians and scientists on (1) current state of the fentanyl crisis and MAT programs, (2) development of novel approaches and therapies for fentanyl-induced addiction and dependence and fentanyl-induced OIRD.

Guest Editor

Prof. Dr. Stephen J. Lewis

Department of Pediatrics, Department of Pharmacology, and Functional Electrical Stimulation Center, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA

Deadline for manuscript submissions

closed (5 March 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/183883

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

